Cancer ResearchRapamycin May Expose a Weakness in Triple-Negative Breast Cancer
Researchers identified a protein called FKBPL that may help triple-negative breast cancer resist a form of cell death driven by iron and damage to cell membrane fats. Higher levels of this protein were associated with worse patient outcomes. Reducing FKBPL slowed cancer cell growth and movement in laboratory experiments and reduced tumor growth in animals. The researchers also reported that rapamycin bound directly to FKBPL and triggered its breakdown, making cancer cells more vulnerable to this death pathway. These findings suggest a possible new treatment strategy, not a proven therapy. The abstract does not report a clinical trial showing that rapamycin benefits women with this cancer. This summary is based only on the abstract, which provides no sample sizes, dosing details, or numerical treatment effects.
